 FOSTER CITY, Calif.--BUSINESS WIRE--Geron Corporation Nasdaq: GERN, a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies, today reported financial results for the fourth quarter and year ended December 31, 2020. The Company ended fiscal year 2020 with 260 million in cash and marketable securities, which is expected to fund operations until the end of 2022. Gerons vision is to be recognized 